2025

Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed

Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria

Press Release: Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD

Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis

Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines

Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors

Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD

Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA

Press Release: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis

Press Release: Availability of the Q1 2025 Aide mémoire

Press Release: Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline

Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD

Press release: Sanofi successfully prices EUR 1.5 billion of bond issue

Media Update: AAD: new data advance Sanofi’s scientific leadership across innovative treatments for inflammatory skin diseases

Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma

Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease

Press Release: Sanofi and CD&R sign Opella share purchase agreement

Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid

Press Release: Filing of the 2024 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report

Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study

Press Release: Execution of a share buyback agreement for up to €2 billion

Media Update: AAAAI: new data reinforce Sanofi’s leadership in immunology and scientific innovation for patients

Press Release: Sanofi announces buy back of shares from L’Oréal

Press Release: Sarclisa is the first anti-CD38 treatment in combination with standard-of-care VRd approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant

Press Release: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025

Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma

Press Release: Opella reaches study milestone for Cialis

Press Release: Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma

Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma